Home
JournalsCollections
For Authors For Reviewers For Editorial Board Members
Article Processing Charges Open Access
Ethics Advertising Policy
Editorial Policy Resource Center
Company Information Contact Us Membership Collaborators Partners
Publications > Journals > Most Viewed Articles
Results per page:
v
Original Article Open Access
UGT1A1 Mutations and Clinical Features in Hereditary Unconjugated Hyperbilirubinemia: A Chinese Cohort Study
Xuheng Teng, Xiaoxiao Mi, Chun Liu, Rongqiang Liu, Zhichao Zhou, Wenjun Yang, Gongying Chen, Junping Shi, Ling Gong
Published online November 13, 2026
Journal of Clinical and Translational Hepatology. doi:10.14218/JCTH.2026.00479
Abstract
Hereditary unconjugated hyperbilirubinemia is most often caused by UGT1A1 mutations and includes Gilbert syndrome, Crigler-Najjar syndrome types I and II, and prolonged neonatal [...] Read more.

Hereditary unconjugated hyperbilirubinemia is most often caused by UGT1A1 mutations and includes Gilbert syndrome, Crigler-Najjar syndrome types I and II, and prolonged neonatal unconjugated hyperbilirubinemia. In Chinese patients, however, the variant spectrum and its clinical relevance remain incompletely characterized. We therefore aimed to define the UGT1A1 variant profile and assess genotype-phenotype correlations in a Chinese cohort.

We retrospectively analyzed 163 patients from the Affiliated Hospital of Hangzhou Normal University (2016–2025). Sanger sequencing of UGT1A1 was performed, covering the enhancer, promoter, and all coding regions. The association between variant types and total serum bilirubin levels was evaluated.

UGT1A1 variants were detected in 156 patients (95.7%), covering 19 distinct variants, including two previously unreported candidate variants (c.272C>G and c.556delinsAATGG). The most common alleles were c.-3279T>G (allele frequency: 0.68), (TA)6>(TA)7 (0.49), and p.G71R (0.23). Coding-region variants were observed more frequently in the Crigler-Najjar syndrome type II group than in the Gilbert syndrome group (P < 0.05), while total bilirubin levels were higher with both coding and non-coding variants than with non-coding variants alone (adjusted P < 0.05 by Dunn’s test), although median-regression confidence intervals included zero.

UGT1A1 genotyping yields a variant detection rate of 95.7% and identifies two previously unreported candidate variants in this Chinese cohort. Exploratory analyses suggest higher bilirubin levels in patients carrying both coding and non-coding variants than in those carrying non-coding variants alone, warranting confirmation in larger cohorts.

Full article
Original Article Open Access
Three Latent Immune-metabolic Dimensions Improve Prediction of ACLF and Mortality in Acute Decompensation of Cirrhosis
Ruiqi Li, Hao Ren, Junyi Wen, Jiale Shen, Jun Guo, Xiaoying Dong, Shuling Chen, Hongli Liu, Caiyun Zhang, Changhua Yi, Wei Chen, Qingfang Xiong, Wei Zhang, Xixuan Wang, Yuzheng Zhuge, Yongfeng Yang
Published online November 13, 2026
Journal of Clinical and Translational Hepatology. doi:10.14218/JCTH.2026.00433
Abstract
Acute decompensation (AD) of cirrhosis has heterogeneous outcomes; existing scores incompletely capture the immune-metabolic mechanisms associated with progression to acute-on-chronic [...] Read more.

Acute decompensation (AD) of cirrhosis has heterogeneous outcomes; existing scores incompletely capture the immune-metabolic mechanisms associated with progression to acute-on-chronic liver failure (ACLF). We aimed to construct and evaluate three latent immune-metabolic dimensions (hyperinflammation, immunoparalysis, and defense-reserve depletion), identify exploratory unsupervised phenotypes, and assess their incremental predictive value beyond The Model for End-Stage Liver Disease (MELD) and Chronic Liver Failure Consortium Acute Decompensation (CLIF-C AD) scores.

In this ambispective cohort study, 485 prospectively enrolled patients formed the discovery cohort (January 2024–September 2025), and 623 patients formed the same-center historical evaluation cohort (December 2019–December 2023). Eleven biomarkers were modeled via exploratory and confirmatory factor analysis. Gaussian mixture modeling identified three phenotypes. Tiered models were compared using Fine-Gray regression and competing-risk-aware performance measures for 90-day ACLF (primary endpoint), and Cox regression and survival performance measures for 90-day mortality.

In the historical evaluation cohort, all three dimensions were independently associated with 90-day ACLF and mortality; immunoparalysis was most strongly associated with ACLF (subdistribution hazard ratio 1.92 per 1 standard deviation [SD], 95% confidence interval [CI] 1.56–2.35; P < 0.001). The Depleted phenotype (P3, approximately 5%) had 90-day ACLF cumulative incidences of 56.0% (discovery) and 66.7% (historical evaluation). In the historical evaluation cohort, FS2-MELD achieved an area under the curve (AUC) of 0.793 (95% CI 0.748–0.832) for 90-day ACLF, versus 0.711 (0.661–0.756) for FS0-MELD (ΔAUC = 0.082; P < 0.001).

Three immune-metabolic dimensions derived from admission biomarkers improve ACLF and mortality prediction beyond conventional scores in AD of cirrhosis, with immunoparalysis showing the strongest prognostic association.

Full article
Review Article Open Access
Selected Extracorporeal Treatment Options in Acute Poisoning: A Focused Narrative Review of Hemoadsorption in Clinical Practice
Gerd Klinkmann, Claudio Ronco, on behalf of the Studies Utilizing Blood Purification in Limiting the Overdose in Treatments (SUBPLOT) Investigators
Published online September 30, 2026
Journal of Translational Critical Care Medicine. doi:10.14218/JTCCM.2026.00004S
Abstract
Extracorporeal treatment (ECTR) is used in selected severe poisonings to enhance toxin elimination and, in some cases, provide temporary organ support. Modalities include intermittent [...] Read more.

Extracorporeal treatment (ECTR) is used in selected severe poisonings to enhance toxin elimination and, in some cases, provide temporary organ support. Modalities include intermittent hemodialysis, continuous renal replacement therapy, and sorbent-based hemoperfusion or hemoadsorption, each with distinct mechanisms and toxicokinetic implications. This narrative review summarizes modality-specific and toxin-specific evidence, operational treatment characteristics, patient-centered and toxicokinetic outcomes, safety considerations, and scenarios in which ECTR should be withheld, and proposes a practical five-step bedside algorithm. Sources were identified through targeted searches of PubMed/MEDLINE and Google Scholar, supplemented by Extracorporeal Treatments in Poisoning (EXTRIP) consensus documents, reference-list screening, and author expertise. The evidence base varies substantially across toxins. For several pharmaceutical poisonings, EXTRIP provides the most actionable guidance on indications, preferred modality, and stopping criteria, while recommending against ECTR for digoxin and methotrexate. Outside these consensus-guided settings, the largest experience with sorbent therapies concerns paraquat and organophosphorus/carbamate poisoning, although the literature is regionally concentrated and predominantly observational. In paraquat poisoning, hemoadsorption-containing strategies have been associated with improved survival in observational cohorts, while pharmacokinetic studies support early and repeated treatment in selected patients because of ongoing toxin removal and post-treatment rebound. In organophosphorus/carbamate poisoning, comparative studies suggest possible benefit in severe presentations, but certainty remains low. In diquat poisoning, recent reports emphasize concentration-directed extracorporeal strategies. Evidence for other toxins is largely limited to feasibility, toxin removal, and case-based experience. ECTR should therefore be regarded as a toxin-specific therapeutic toolbox rather than a uniform intervention. Where available, EXTRIP recommendations should guide practice. Otherwise, modality selection should integrate toxicokinetic plausibility, clinical severity, feasibility, and safety. Prospective studies using standardized prescriptions and clinically meaningful endpoints are needed.

Full article
Review Article Open Access
Gluten-free Diet and Metabolic Dysfunction-associated Steatotic Liver Disease: Mechanisms and Therapeutic Potential
Di Meng, Zhenyao Jiang, Yingcheng Yao, Mingming Ye, Sitian Zhao, Mingyang Jin, Jie Li, Junping Shi
Published online November 16, 2026
Journal of Clinical and Translational Hepatology. doi:10.14218/JCTH.2026.00242
Abstract
Metabolic dysfunction-associated steatotic liver disease (MASLD) is a chronic liver disease associated with obesity, insulin resistance, and metabolic syndrome and has become a [...] Read more.

Metabolic dysfunction-associated steatotic liver disease (MASLD) is a chronic liver disease associated with obesity, insulin resistance, and metabolic syndrome and has become a major global health challenge. Current management relies primarily on comprehensive lifestyle interventions, including dietary modification, regular physical activity, weight loss, management of metabolic risk factors, and emerging pharmacotherapies. The gluten-free diet (GFD) was originally developed for the treatment of celiac disease and has attracted attention in recent years for its potential metabolic benefits. Existing studies suggest that gluten- or wheat-targeted dietary interventions may affect MASLD-related pathways, including the gut microbiota, inflammation, insulin sensitivity, and liver fat accumulation. In patients with concurrent celiac disease and MASLD, a GFD is indicated for celiac disease, but its hepatic and metabolic effects are variable. However, clinical and mechanistic evidence for its potential effects in patients with non-celiac MASLD is limited and heterogeneous, relying largely on indirect evidence from animal models; furthermore, long-term, unsupervised adherence to a GFD may adversely affect metabolic health. This narrative review critically evaluates the therapeutic boundaries of gluten-targeted interventions, compares the gluten-free diet with established dietary patterns, and outlines challenges related to nutritional adequacy, cost, and adherence. Future research should focus on high-quality randomized controlled trials to identify the specific benefits and risks of gluten removal in patients with non-celiac MASLD and to inform more precise dietary guidance.

Full article
Review Article Open Access
Chronic Constipation: Mechanisms and Roadmap for Testing Candidate Endotypes
Elena Bonora, Elisa Boschetti, Visha Parmar, Saranya Arumugam, Roberto De Giorgio, Shanthi Srinivasan, John W. Wiley
Published online November 16, 2026
Journal of Translational Gastroenterology. doi:10.14218/JTG.2026.00033
Abstract
Chronic constipation is common, heterogeneous, and often incompletely controlled. This review evaluates cellular and molecular evidence and proposes a roadmap for testing candidate [...] Read more.

Chronic constipation is common, heterogeneous, and often incompletely controlled. This review evaluates cellular and molecular evidence and proposes a roadmap for testing candidate endotypes. We distinguish established physiology and clinical efficacy from human associations, causal effects in experimental systems, and unvalidated hypotheses. Relevant mechanisms involve enteric neurons and glia, pacemaker and smooth muscle networks, epithelial transport, enteroendocrine signaling, microbial metabolites, and pelvic floor coordination. Five candidate endotypes address neuronal composition, pacemaker dysfunction, methanogen enrichment, neuroimmune activation, and cortical–pelvic coordination; pharmacogenomics provides a cross-cutting strategy. Each proposal links measurable features to appropriate sampling and prospective tests that can exclude clinically meaningful effects. Cellular sequencing, spatial RNA and protein profiling, and multimodal integration can identify candidate signatures. Organoid and animal perturbations test mechanisms within models; clinical usefulness additionally requires reproducible assays, independent validation, randomized treatment-interaction tests, and patient benefit. Rome V criteria provide a cohort framework, with the criteria version recorded explicitly. A staged program should begin with clinical phenotyping and biospecimen banking, add mucosal studies, and develop multicenter full-thickness tissue collections for neuromuscular questions. This approach addresses cost, selection bias, and tissue access while distinguishing mechanistic discovery from useful treatment guidance.

Full article
Original Article Open Access
Jaundice Is Associated with Intraoperative Hypotension, Suppressed Immune–endothelial NF-κB/EDN1 Signaling, and Impaired Vascular Cell Function
Gen Li, Ming Cheng, Jian He, Dengfeng Huang, Yingying Zhou, Yaohui Gao, Yuming Sun, Zhizhen Li
Published online November 17, 2026
Journal of Clinical and Translational Hepatology. doi:10.14218/JCTH.2026.00174
Abstract
Intraoperative hypotension (IOH) is a common and serious complication associated with increased perioperative morbidity and mortality. Although obstructive jaundice is often accompanied [...] Read more.

Intraoperative hypotension (IOH) is a common and serious complication associated with increased perioperative morbidity and mortality. Although obstructive jaundice is often accompanied by hemodynamic instability, its mechanistic contribution to IOH remains unclear. In this study, we aimed to determine whether jaundice affects IOH and elucidate the underlying mechanism.

Clinical data from 139 patients who underwent pancreatoduodenectomy were retrospectively analyzed for predictors of IOH. Vascular tissues from jaundiced and non-jaundiced patients were subjected to single-cell RNA sequencing for cell-specific molecular exploration. Key findings were validated by immunohistochemistry in a stratified random sample from the study cohort. In a rat bile duct ligation model, aortic endothelin-1 (EDN1) expression and vascular function were assessed by Western blotting and ex vivo vascular reactivity assays. The mechanism was investigated in primary mouse aortic endothelial cells under TNF-α stimulation with or without NF-κB pathway inhibition.

Multivariable logistic regression identified jaundice as an independent predictor of IOH (odds ratio, 2.328; 95% confidence interval, 1.027–5.276; P = 0.043). Jaundiced tissues exhibited vascular cell remodeling, characterized by increased proportions of endothelial cells and macrophages and decreased proportions of fibroblasts and smooth muscle cells. EDN1 expression was significantly downregulated in jaundiced patients, and total bilirubin levels were negatively correlated with EDN1 protein expression (P < 0.001). Single-cell RNA sequencing of immune cells suggested suppression of the NF-κB pathway in jaundiced patients. In the bile duct ligation model, EDN1 expression in aortic tissue showed a time-dependent decrease. In TNF-α-stimulated primary mouse aortic endothelial cells, bilirubin or NF-κB inhibition with BAY 11-7082 suppressed EDN1 expression.

Biliary obstruction causing jaundice may contribute to IOH through suppression of NF-κB signaling and reduced endothelial EDN1 expression. These findings support further investigation of the NF-κB/EDN1 signaling axis as a potential therapeutic target for jaundice-associated IOH.

Full article
Review Article Open Access
Midnight-noon Ebb-flow (Ziwu Liuzhu) and Circadian Science: Comparison of Two Temporalized Models of the Body
Kao-Cheng Huang, Ya-Ning Chang
Published online November 17, 2026
Future Integrative Medicine. doi:10.14218/FIM.2026.00026
Abstract
Midnight-noon ebb-flow (ziwu liuzhu) and circadian science are both temporalized models of the body, treating time of day as an intrinsic variable of physiology and therapeutic [...] Read more.

Midnight-noon ebb-flow (ziwu liuzhu) and circadian science are both temporalized models of the body, treating time of day as an intrinsic variable of physiology and therapeutic response, yet they differ fundamentally in theoretical units, causal claims, and standards of evidence. Ziwu liuzhu, a time-function model of traditional Chinese medicine, maps the 12 double-hours (shichen) onto the ebb and flow of qi and blood in the 12 channels (meridians); circadian science, an experimentally grounded mechanistic model, describes circadian rhythms generated by an endogenous, light-entrained timing system of the suprachiasmatic nucleus, clock genes, and peripheral clocks. Existing accounts tend either to conflate the two frameworks or to dismiss one in terms of the other. This narrative review compares the two frameworks’ conceptual structure, historical formation, mechanisms, evidence, and applications. Their genuine convergence lies in treating time as a variable in health and disease, not in any proven mechanism. Chronotherapy findings likewise do not validate the channel-hour correspondences. Fixed double-hour assignments do not correspond to the phase-adjustable, individually variable circadian system; the morphological basis of the channels remains unconfirmed; and the certainty of evidence for a timing-specific effect of ziwu liuzhu acupuncture appears low to very low. We distinguish three critical issues that are often conflated: the efficacy of timed acupuncture, its mechanism, and the anatomical status of the channels; evidence on the first two does not settle the third. We propose a layered research agenda that preserves the tradition’s historical and clinical value while rigorously evaluating its testable claims, chiefly through trials comparing identical needling given on-time and off-time, scheduled both by classical clock time and relative to measured circadian phase. We conclude that ziwu liuzhu is best treated as a source of testable hypotheses, and that no clinical efficacy should be claimed for its timing principle until it has been demonstrated.

Full article
Original Article Open Access
MOLLI Seed and Surgical Margin Status in Breast-conserving Surgery: An Exploratory Study
Lucy Ogoke, Sangwook Michael Woo, Nicole Herbers, Michael Chen, Hua Yang, Amy Bazzarelli, Wei Xiong
Published online November 17, 2026
Journal of Clinical and Translational Pathology. doi:10.14218/JCTP.2026.00043
Abstract
Fine-wire-guided localization (FWGL) has traditionally been used for nonpalpable breast lesions although it can complicate specimen handling. Magnetic Occult Lesion Localization [...] Read more.

Fine-wire-guided localization (FWGL) has traditionally been used for nonpalpable breast lesions although it can complicate specimen handling. Magnetic Occult Lesion Localization and Imaging (MOLLI) is a wire-free alternative for which comparative pathologic data remain limited. This exploratory study examined margin status, morphometry, and specimen integrity.

We retrospectively analyzed 109 consecutive lumpectomy specimens (83 MOLLI, 26 FWGL) at a single academic center between March 2022 and April 2023, comprising 108 primary excisions and one re-excision. The localization method was not randomly assigned and appears to have depended on surgeon preference. Secondary invasive-carcinoma analyses used Firth penalized logistic regression to adjust for potential confounding.

After exclusion of 33 benign lesions, 76 carcinomas remained (62 invasive carcinomas and 14 cases of pure ductal carcinoma in situ), 75 with evaluable primary-excision margins. For the primary outcome, positive margins occurred in 13.8% (8/58) of MOLLI versus 17.6% (3/17) of FWGL cases (P = 0.70). In the secondary invasive-carcinoma analysis, positive margins occurred in 10.9% (5/46) versus 18.8% (3/16) (P = 0.41). Median specimen weight and volume did not differ significantly; specimen integrity was preserved in 98.8% (82/83) of MOLLI and 100% (26/26) of FWGL specimens.

In this exploratory study, MOLLI shows no detectable differences in margin status, morphometry, or specimen integrity relative to fine-wire localization. Unlike published data on a related magnetic-seed device, we observe no reduction in resected tissue volume, indicating that findings for one device should not be assumed to apply to another. The study is underpowered to detect small differences. These preliminary findings therefore require confirmation in larger studies.

Full article
Review Article Open Access
From Germline Susceptibility to Somatic Evolution: The Genetic Trajectory of Pancreatic Ductal Adenocarcinoma and Implications for Screening and Early Detection
Chenshan Ma, Hanyu Zhu, Zhenyu Li, Yichen Qiu, Xue Liu, Xinyue Zhai, Kuirong Jiang, Zipeng Lu, Wentao Gao, Lingdi Yin
Published online November 16, 2026
Cancer Screening and Prevention. doi:10.14218/CSP.2026.00014
Abstract
Pancreatic ductal adenocarcinoma (PDAC) is often diagnosed too late for curative resection, and durable responses to systemic therapy remain uncommon. However, research on inherited [...] Read more.

Pancreatic ductal adenocarcinoma (PDAC) is often diagnosed too late for curative resection, and durable responses to systemic therapy remain uncommon. However, research on inherited susceptibility, precursor lesions, and somatic evolution has often developed separately, obscuring a unified view of disease progression. Here, we integrate these areas within a germline-to-somatic framework, including limited Asian-population evidence, and examine implications for inherited-risk assessment, high-risk surveillance, early detection, and treatment selection. Pathogenic germline variants occur in a minority of patients, affecting pathways involved in homologous recombination repair, DNA damage responses, cell-cycle control, mismatch repair, and pancreatitis susceptibility. Common susceptibility alleles exert smaller individual effects and may refine multifactorial risk models. Biallelic inactivation of BRCA1, BRCA2, or PALB2 can produce homologous recombination deficiency and extensive structural variation, potentially increasing platinum sensitivity. Randomized evidence supports maintenance olaparib for metastatic PDAC with pathogenic germline BRCA1 or BRCA2 variants after at least 16 weeks of platinum-based chemotherapy without disease progression. Tumor initiation proceeds through several precursor routes. Pancreatic intraepithelial neoplasia commonly acquires early KRAS mutations, while additional tumor-suppressor and chromosomal alterations accompany progression. Acinar-to-ductal metaplasia creates a plastic cell state that can support KRAS-driven neoplasia after injury. Intraductal papillary mucinous neoplasms may follow branching or multiclonal trajectories involving KRAS, GNAS, and RNF43. After invasion, gradual driver accumulation coexists with punctuated genome remodeling. Copy-number evolution, transcriptional plasticity, and subclonal selection continue during metastatic dissemination and treatment. Clinical translation includes germline testing for all patients with PDAC and imaging-based surveillance for individuals with defined genetic or familial risk. Tumor profiling informs treatment selection in actionable subgroups, whereas blood-based early detection and longitudinal molecular monitoring remain investigational. Overall, PDAC follows a branching genetic trajectory that informs risk stratification and molecular treatment selection. Further progress requires ancestry-diverse paired germline-tumor sequencing, multiregion and single-cell analyses, and prospective validation of clinically relevant biomarkers.

Full article
Letter to the Editor Open Access
Interpreting the Association Between Hypertension and Extrahepatic Cancers in MASLD: Insights from NHANES
Jiale Tang, Lingyu Ren, Chao Sun, You Deng
Published online November 17, 2026
Journal of Clinical and Translational Hepatology. doi:10.14218/JCTH.2026.00704
PrevPage 35 of 36 12…3233343536Next